First Allogeneic CAR T Ph 2 ALPHA2 Trial of ALLO-501A in R/R LBCL Patients initiated October 12, 2022
Ph 1/2 Trial of ABC008 initiated in Patients with T Cell Large Granular Lymphocytic Leukemia October 12, 2022
First Patient Treated in Ph 1/2 Clinical Trial of MB-106 in B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia October 12, 2022
Part 3 of the CORIST Ph 2 trial of SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC) initiated October 12, 2022
Randomized Ph 2 trial of onvansertib + SoC FOLFIRI/bevacizumab announced in 2L RAS-mutated mCRC September 28, 2022
Pivotal Ph 3 Trial of Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer initiated September 28, 2022
Enrollment of the Ph 1/2 OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer completed September 28, 2022
First Patient Dosed In Ph 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3 September 7, 2022
Enrollment initiated in Ph 2 Trial of Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma September 7, 2022
Ph 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded; additional cohort to test SCIB1 vaccine in combination with checkpoint doublet therapy June 16, 2022
FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab June 14, 2022
Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved June 13, 2022
Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways June 13, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
First patient dosed with ADG106 + ADG116 combination in Ph 1b/2 trial in solid tumors January 28, 2022
First Patient Treated in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer April 21, 2021
